Cargando…

Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury

Glucagon-like peptide-1 (GLP-1) is glucose-dependent insulinotropic hormone secreted from enteroendocrine L cells. Its long-acting analogue, exendin-4, is equipotent to GLP-1 and is used to treat type 2 diabetes mellitus. In addition, exendin-4 has effects on the central and peripheral nervous syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Koji, Amako, Masatoshi, Yamamoto, Yoritsuna, Tsuchihara, Toyokazu, Nukada, Hitoshi, Yoshihara, Yasuo, Arino, Hiroshi, Fujita, Masanori, Uenoyama, Maki, Tachibana, Shoichi, Nemoto, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747455/
https://www.ncbi.nlm.nih.gov/pubmed/23984340
http://dx.doi.org/10.1155/2013/315848
_version_ 1782280939383029760
author Yamamoto, Koji
Amako, Masatoshi
Yamamoto, Yoritsuna
Tsuchihara, Toyokazu
Nukada, Hitoshi
Yoshihara, Yasuo
Arino, Hiroshi
Fujita, Masanori
Uenoyama, Maki
Tachibana, Shoichi
Nemoto, Koichi
author_facet Yamamoto, Koji
Amako, Masatoshi
Yamamoto, Yoritsuna
Tsuchihara, Toyokazu
Nukada, Hitoshi
Yoshihara, Yasuo
Arino, Hiroshi
Fujita, Masanori
Uenoyama, Maki
Tachibana, Shoichi
Nemoto, Koichi
author_sort Yamamoto, Koji
collection PubMed
description Glucagon-like peptide-1 (GLP-1) is glucose-dependent insulinotropic hormone secreted from enteroendocrine L cells. Its long-acting analogue, exendin-4, is equipotent to GLP-1 and is used to treat type 2 diabetes mellitus. In addition, exendin-4 has effects on the central and peripheral nervous system. In this study, we administered repeated intraperitoneal (i.p.) injections of exendin-4 to examine whether exendin-4 is able to facilitate the recovery after the crush nerve injury. Exendin-4 injection was started immediately after crush injury and was repeated every day for subsequent 14 days. Rats subjected to sciatic nerve crush exhibited marked functional loss, electrophysiological dysfunction, and atrophy of the tibialis anterior muscle (TA). All these changes, except for the atrophy of TA, were improved significantly by the administration of exendin-4. Functional, electrophysiological, and morphological parameters indicated significant enhancement of nerve regeneration 4 weeks after nerve crush. These results suggest that exendin-4 is feasible for clinical application to treat peripheral nerve injury.
format Online
Article
Text
id pubmed-3747455
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37474552013-08-27 Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury Yamamoto, Koji Amako, Masatoshi Yamamoto, Yoritsuna Tsuchihara, Toyokazu Nukada, Hitoshi Yoshihara, Yasuo Arino, Hiroshi Fujita, Masanori Uenoyama, Maki Tachibana, Shoichi Nemoto, Koichi Biomed Res Int Research Article Glucagon-like peptide-1 (GLP-1) is glucose-dependent insulinotropic hormone secreted from enteroendocrine L cells. Its long-acting analogue, exendin-4, is equipotent to GLP-1 and is used to treat type 2 diabetes mellitus. In addition, exendin-4 has effects on the central and peripheral nervous system. In this study, we administered repeated intraperitoneal (i.p.) injections of exendin-4 to examine whether exendin-4 is able to facilitate the recovery after the crush nerve injury. Exendin-4 injection was started immediately after crush injury and was repeated every day for subsequent 14 days. Rats subjected to sciatic nerve crush exhibited marked functional loss, electrophysiological dysfunction, and atrophy of the tibialis anterior muscle (TA). All these changes, except for the atrophy of TA, were improved significantly by the administration of exendin-4. Functional, electrophysiological, and morphological parameters indicated significant enhancement of nerve regeneration 4 weeks after nerve crush. These results suggest that exendin-4 is feasible for clinical application to treat peripheral nerve injury. Hindawi Publishing Corporation 2013 2013-08-04 /pmc/articles/PMC3747455/ /pubmed/23984340 http://dx.doi.org/10.1155/2013/315848 Text en Copyright © 2013 Koji Yamamoto et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yamamoto, Koji
Amako, Masatoshi
Yamamoto, Yoritsuna
Tsuchihara, Toyokazu
Nukada, Hitoshi
Yoshihara, Yasuo
Arino, Hiroshi
Fujita, Masanori
Uenoyama, Maki
Tachibana, Shoichi
Nemoto, Koichi
Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
title Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
title_full Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
title_fullStr Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
title_full_unstemmed Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
title_short Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
title_sort therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747455/
https://www.ncbi.nlm.nih.gov/pubmed/23984340
http://dx.doi.org/10.1155/2013/315848
work_keys_str_mv AT yamamotokoji therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT amakomasatoshi therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT yamamotoyoritsuna therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT tsuchiharatoyokazu therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT nukadahitoshi therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT yoshiharayasuo therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT arinohiroshi therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT fujitamasanori therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT uenoyamamaki therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT tachibanashoichi therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury
AT nemotokoichi therapeuticeffectofexendin4alongactinganalogueofglucagonlikepeptide1receptoragonistonnerveregenerationafterthecrushnerveinjury